CA-CROWN-BIOSCIENCE
3.6.2021 14:32:09 CEST | Business Wire | Press release
Crown Bioscience (CrownBio), a JSR Life Sciences Company, today announced that they have entered into separate, yet complementary, portfolio license agreements with the ATCC and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute (NCI) of the National Institute of Health (NIH). By entering into five-year agreements with these premier biomaterial resource providers, CrownBio clients will directly benefit from a priority status that will make cell lines more readily available with simplified logistics.
Through its XenoSelect™ and OmniScreen™ panels, CrownBio already offers its clients highly customizable, broad in vitro screening panel services, paired with industry-leading bioinformatics capabilities and a breadth of established “matched” downstream in vivo models. CrownBio clients will now have access to an extended and unrivaled portfolio of cell lines, with the knowledge and peace of mind that all necessary licensing is in place.
The license agreement with ATCC grants CrownBio expedited access to more than 140 cell lines and associated datasets, as well as future access to an additional 4000 cell lines through an umbrella licensing structure. Similarly, to meet CrownBio’s ongoing global client needs for supplies of NIH cell lines, a new portfolio license has been signed with the NIH. With this agreement, CrownBio will provide access to 100 cell lines available through the NCI Repository of Tumors and Tumor Cell Lines and other sources, that were developed in NCI labs.
Henry Li, PhD, CSO of CrownBio said, “We greatly value our relationships with both ATCC and NIH, which are two of CrownBio’s largest cell line partners. We are excited that these new agreements will enable us to offer our clients expanded and prioritized cell line availability and supply. Together, these agreements exemplify CrownBio’s dedication to ensuring our clients have easy access to an industry-leading range of in vitro and in vivo models for drug discovery.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and immune-mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005538/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grand Prix ACF AutoTech 2026 Unveils Its Six Finalist Startups10.2.2026 19:31:00 CET | Press release
The jury of the Grand Prix ACF AutoTech 2026, which met on February 9 at the Automobile Club de France, has selected six finalist startups following several hours of deliberation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210456562/en/ Jury members The selected companies stand out for their technological ambition, economic viability and tangible impact on automotive cost reduction and industrial performance. Key themes this year include AI-assisted engineering design, strategic independence from critical materials, and advanced LiDAR optimization. Finalist startups include: Grand Prix ACF (Mature startups) - Altrove (Paris, France): Develops innovative alternatives to high-risk critical inorganic materials using a proprietary algorithmic approach and unique artificial intelligence, strengthening industrial resilience and technological sovereignty. - Cognitive Design Systems (Toulouse, France): Provides an AI-powered
Second to None in Business Excellence: Mary Kay Named #2 on the Forbes 2026 Best Customer Service List10.2.2026 17:01:00 CET | Press release
Mary Kay Wraps up 2025 with 25 Corporate Reputation Awards Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. The honor follows a standout year for Mary Kay, which concluded 2025 with a total of 25 global awards, underscoring its continued focus on corporate excellence, direct selling industry, social impact, environmental sustainability, science, and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210599426/en/ Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. (Image Courtesy: Mary Kay Inc.) The recent recognition highlights Mary Kay’s enduring commitment to putting the custome
Interactive Brokers Expands Crypto Futures Offering with Coinbase Derivatives10.2.2026 16:15:00 CET | Press release
Select nano and Perpetual Style Futures Contracts Available Around the Clock Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Coinbase Derivatives, LLC nano Bitcoin and nano Ether futures contracts for trading on the IBKR platform. These new products are available with monthly expirations or as perpetual-style contracts, offering eligible clients a cost-effective way to gain exposure to cryptocurrency and manage risk within a regulated framework, with trading available 24/7. Clients of Interactive Brokers can access more than 170 markets worldwide and trade both traditional instruments and digital assets from a single platform. The new Coinbase Derivatives contracts offer an easier way to manage cryptocurrency exposure, with lower capital requirements and transparent trading on a regulated exchange. Nano futures are smaller-sized contracts, such as 0.01 Bitcoin and 0.10 Ether, that lower entry costs and allow for more precise posi
Golub Capital Expands Broadly Syndicated Loan CLO Business to Europe10.2.2026 15:00:00 CET | Press release
The Firm brings credit-first, top performing platform to meet demand from European partnersIndustry veteran Tyler Wallace appointed to lead strategy in London Today, Golub Capital (“the Firm”) announced the expansion of its BSL CLO strategy to Europe and the appointment of Tyler Wallace as Managing Director, European Broadly Syndicated Loans. Wallace brings more than 20 years of leading credit experience to the Firm and most recently was a Managing Director and Portfolio Manager of CLOs at Fair Oaks Capital in London. “This is a natural expansion for us,” said Scott Morrison, Head of BSL at Golub Capital. “The expansion builds on our market-leading U.S. CLO platform and strengthens our ability to deliver comprehensive financing solutions to partners across Europe.” Said Tyler Wallace, “Golub Capital has an exceptional BSL track record. I am excited to lead this next chapter and bring the Firm’s capabilities to partners in the region.” As of December 31, 2025, Golub Capital manages over
Draslovka and Avathon Partner to Deliver AI-Powered Solutions for Mining Through Autonomy, MetOptima and Blue Cube Combined Offering10.2.2026 15:00:00 CET | Press release
Draslovka a.s. (“Draslovka”), a global innovator in sustainable chemical technologies and AI‑enabled services for the mining sector, and Avathon, the leader in Autonomy for Operations, today announced a strategic commercial partnership to accelerate the adoption of intelligent, autonomous, and data‑driven operations across the global mining industry. The partnership provides a breakthrough solution that combines Draslovka’s real‑time mineral and slurry monitoring technologies—delivered through its world class Blue Cube on‑stream mineralogical sensors—and MetOptima advanced metallurgical optimization AI engine, with the Avathon Autonomy Platform, a scalable industrial‑AI environment that enhances operational performance, automating decisions, and orchestrating complex operations across sites. Under the agreement, Draslovka and Avathon will collaborate closely on go-to-market initiatives, jointly commercializing and cross‑selling the combined offering. The combined Draslovka‑Avathon offe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom